Page last updated: 2024-11-07

n(omega)-hydroxyarginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(omega)-hydroxyarginine: can cause vasorelaxation of bovine intrapulmonary artery; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(5)-[(Z)-amino(hydroxyimino)methyl]-L-ornithine : An N(5)-[amino(hydroxyimino)methyl]-L-ornithine in which the double bond has Z-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123895
CHEBI ID43088
CHEBI ID47822
CHEBI ID47819
CHEBI ID47821
SCHEMBL ID448333
MeSH IDM0186877

Synonyms (38)

Synonym
lopac-h-7278
NCGC00015515-01
LOPAC0_000615
n-omega-hydroxy-l-arginine
C05933
n(omega)-hydroxy-l-arginine
n(omega)-hydroxyarginine
53054-07-2
DB03144
CHEBI:43088 ,
n(5)-(n-hydroxycarbamimidoyl)-l-ornithine
1HQF ,
n(5)-[(hydroxyamino)(imino)methyl]-l-ornithine
CHEBI:47822
n(5)-[(z)-amino(hydroxyimino)methyl]-l-ornithine
n(5)-[(e)-amino(hydroxyimino)methyl]-l-ornithine
n(5)-[amino(hydroxyimino)methyl]-l-ornithine
CHEBI:47819
CHEBI:47821
ng-hydroxy-l-arginine acetate
NCGC00162204-01
(2s)-2-amino-5-[[amino-(hydroxyamino)methylidene]amino]pentanoic acid
CCG-204704
unii-j2fgl272nz
l-ornithine, n5-((hydroxyamino)iminomethyl)-
6-noha
j2fgl272nz ,
n(g)-hydroxy-l-arginine
SCHEMBL448333
n5-[(hydroxyamino)iminomethyl]-l-ornithine
omega-hydroxy-l-arginine
n~5~-(n-hydroxycarbamimidoyl)-l-ornithine
nw-hydroxy-l-arginine
Q27094087
n~5~-(n-hydroxycarbamimidoyl)ornithine
DTXSID60967549
l-noha
(2s)-2-amino-5-(n''-hydroxycarbamimidamido)pentanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (7)

ClassDescription
N(5)-[amino(hydroxyimino)methyl]-L-ornithine
N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine
N(omega)-hydroxy-L-arginine
N(5)-[amino(hydroxyimino)methyl]ornithine
N(omega)-hydroxy-L-arginine
N(5)-[(hydroxyamino)(imino)methyl]ornithine
N(5)-[amino(hydroxyimino)methyl]-L-ornithine
N(5)-[(E)-amino(hydroxyimino)methyl]ornithine
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency0.39810.02827.055915.8489AID895; AID928
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.05010.00106.000935.4813AID943
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ARGINASE 1Rattus norvegicus (Norway rat)Ki10.000010.0000505.00001,000.0000AID977610
Chain A, Arginase 1Rattus norvegicus (Norway rat)Ki10.000010.0000505.00001,000.0000AID977610
Chain A, ARGINASE 1Rattus norvegicus (Norway rat)Ki10.000010.0000505.00001,000.0000AID977610
Arginase-1 Rattus norvegicus (Norway rat)IC50 (µMol)20.00000.80001.20002.0000AID1724055
Arginase-2, mitochondrialHomo sapiens (human)Ki1.60000.00850.34381.6000AID1724057
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Arginase-1Homo sapiens (human)Kd3.60000.00500.69873.6000AID1724056
Nitric oxide synthase, inducibleHomo sapiens (human)Kd5.10005.10006.36677.0000AID415946
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nitric oxide synthase, inducibleHomo sapiens (human)Km52.00002.80005.70008.6000AID415945
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
urea cycleArginase-1Homo sapiens (human)
adaptive immune responseArginase-1Homo sapiens (human)
arginine catabolic processArginase-1Homo sapiens (human)
negative regulation of T cell proliferationArginase-1Homo sapiens (human)
defense response to protozoanArginase-1Homo sapiens (human)
innate immune responseArginase-1Homo sapiens (human)
negative regulation of activated T cell proliferationArginase-1Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayArginase-1Homo sapiens (human)
positive regulation of neutrophil mediated killing of fungusArginase-1Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionArginase-1Homo sapiens (human)
arginine catabolic process to ornithineArginase-1Homo sapiens (human)
response to hypoxiaNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of leukocyte mediated cytotoxicityNitric oxide synthase, inducibleHomo sapiens (human)
innate immune response in mucosaNitric oxide synthase, inducibleHomo sapiens (human)
arginine catabolic processNitric oxide synthase, inducibleHomo sapiens (human)
superoxide metabolic processNitric oxide synthase, inducibleHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, inducibleHomo sapiens (human)
circadian rhythmNitric oxide synthase, inducibleHomo sapiens (human)
response to bacteriumNitric oxide synthase, inducibleHomo sapiens (human)
negative regulation of gene expressionNitric oxide synthase, inducibleHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, inducibleHomo sapiens (human)
prostaglandin secretionNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of interleukin-6 productionNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of interleukin-8 productionNitric oxide synthase, inducibleHomo sapiens (human)
regulation of cell population proliferationNitric oxide synthase, inducibleHomo sapiens (human)
negative regulation of protein catabolic processNitric oxide synthase, inducibleHomo sapiens (human)
defense response to bacteriumNitric oxide synthase, inducibleHomo sapiens (human)
regulation of cellular respirationNitric oxide synthase, inducibleHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, inducibleHomo sapiens (human)
regulation of insulin secretionNitric oxide synthase, inducibleHomo sapiens (human)
defense response to Gram-negative bacteriumNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of killing of cells of another organismNitric oxide synthase, inducibleHomo sapiens (human)
cellular response to lipopolysaccharideNitric oxide synthase, inducibleHomo sapiens (human)
cellular response to type II interferonNitric oxide synthase, inducibleHomo sapiens (human)
cellular response to xenobiotic stimulusNitric oxide synthase, inducibleHomo sapiens (human)
regulation of cytokine production involved in inflammatory responseNitric oxide synthase, inducibleHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, inducibleHomo sapiens (human)
response to hormoneNitric oxide synthase, inducibleHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, inducibleHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, inducibleHomo sapiens (human)
inflammatory responseNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, inducibleHomo sapiens (human)
urea cycleArginase-2, mitochondrialHomo sapiens (human)
ureteric bud developmentArginase-2, mitochondrialHomo sapiens (human)
adaptive immune responseArginase-2, mitochondrialHomo sapiens (human)
negative regulation of type 2 immune responseArginase-2, mitochondrialHomo sapiens (human)
nitric oxide biosynthetic processArginase-2, mitochondrialHomo sapiens (human)
striated muscle contractionArginase-2, mitochondrialHomo sapiens (human)
regulation of interleukin-1 beta productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of interleukin-13 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of interleukin-17 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of tumor necrosis factor productionArginase-2, mitochondrialHomo sapiens (human)
innate immune responseArginase-2, mitochondrialHomo sapiens (human)
negative regulation of macrophage inflammatory protein 1 alpha productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of chemokine (C-C motif) ligand 4 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of chemokine (C-C motif) ligand 5 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of defense response to bacteriumArginase-2, mitochondrialHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processArginase-2, mitochondrialHomo sapiens (human)
negative regulation of activated CD8-positive, alpha-beta T cell apoptotic processArginase-2, mitochondrialHomo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell proliferationArginase-2, mitochondrialHomo sapiens (human)
positive regulation of cellular senescenceArginase-2, mitochondrialHomo sapiens (human)
arginine catabolic process to ornithineArginase-2, mitochondrialHomo sapiens (human)
urea cycleArginase-1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
protein bindingArginase-1Homo sapiens (human)
arginase activityArginase-1Homo sapiens (human)
manganese ion bindingArginase-1Homo sapiens (human)
nitric-oxide synthase activityNitric oxide synthase, inducibleHomo sapiens (human)
protein bindingNitric oxide synthase, inducibleHomo sapiens (human)
calmodulin bindingNitric oxide synthase, inducibleHomo sapiens (human)
FMN bindingNitric oxide synthase, inducibleHomo sapiens (human)
heme bindingNitric oxide synthase, inducibleHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, inducibleHomo sapiens (human)
arginine bindingNitric oxide synthase, inducibleHomo sapiens (human)
protein homodimerization activityNitric oxide synthase, inducibleHomo sapiens (human)
metal ion bindingNitric oxide synthase, inducibleHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, inducibleHomo sapiens (human)
NADP bindingNitric oxide synthase, inducibleHomo sapiens (human)
arginase activityArginase-2, mitochondrialHomo sapiens (human)
protein bindingArginase-2, mitochondrialHomo sapiens (human)
manganese ion bindingArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
extracellular regionArginase-1Homo sapiens (human)
extracellular spaceArginase-1Homo sapiens (human)
nucleusArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
azurophil granule lumenArginase-1Homo sapiens (human)
specific granule lumenArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
cytoplasmArginase-1Homo sapiens (human)
nucleusNitric oxide synthase, inducibleHomo sapiens (human)
nucleoplasmNitric oxide synthase, inducibleHomo sapiens (human)
cytoplasmNitric oxide synthase, inducibleHomo sapiens (human)
peroxisomeNitric oxide synthase, inducibleHomo sapiens (human)
peroxisomal matrixNitric oxide synthase, inducibleHomo sapiens (human)
cytosolNitric oxide synthase, inducibleHomo sapiens (human)
cortical cytoskeletonNitric oxide synthase, inducibleHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, inducibleHomo sapiens (human)
plasma membraneNitric oxide synthase, inducibleHomo sapiens (human)
nucleusNitric oxide synthase, inducibleHomo sapiens (human)
cytosolNitric oxide synthase, inducibleHomo sapiens (human)
mitochondrial matrixArginase-2, mitochondrialHomo sapiens (human)
cytoplasmArginase-2, mitochondrialHomo sapiens (human)
mitochondrionArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID756826Induction of xanthine/xanthine oxidase-mediated NOx production at 100 uM after 1 hr by Griess test in presence of allopurinol2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1189986Displacement of imidazole from Bacillus subtilis NOS2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Structure-based design of bacterial nitric oxide synthase inhibitors.
AID756818Vasodilatory activity in Wistar rat endothelium-intact aorta assessed as reduction of acetylcholine-induced vasoconstriction at 100 uM2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID756817Vasodilatory activity in Wistar rat endothelium-intact aorta assessed as reduction of acetylcholine-induced vasoconstriction at 100 uM in presence of L-NAME2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1629627Substrate activity at recombinant mouse iNOS assessed as increase in NO release incubated for 30 mins in presence of NADPH followed by LDH and sodium pyruvate addition measured after 15 mins by Griess assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.
AID1189988Displacement of imidazole from Bacillus subtilis iNOS in presence of 50 uM H4B2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Structure-based design of bacterial nitric oxide synthase inhibitors.
AID1629630Toxicity in mouse J744A.1 cells assessed as reduction in cell proliferation up to 1 mM after 2.5 hrs by Hoechst 33342/DAF-FM-DA staining based fluorescence microscopic analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.
AID1629628Toxicity in mouse J744A.1 cells assessed as changes in cell shape up to 1 mM after 2.5 hrs by Hoechst 33342/DAPI/GFP staining based fluorescence microscopic analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.
AID1724056Binding affinity to human Arg1 at pH 8.52020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Boronic acid-based arginase inhibitors in cancer immunotherapy.
AID756828Induction of NOx production in Wistar rat renal cortex homogenates at 100 uM after 1 hr by Griess test2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID756822Induction of xanthine/xanthine oxidase-mediated NOx production at 100 uM after 1 hr by Griess test in presence of gamma-glutamyl transpeptidase2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID756819Induction of NOx production in Wistar rat renal medullar homogenates at 100 uM after 1 hr by Griess test in presence of gamma-glutamyl transpeptidase2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID756810Vasodilatory activity in Wistar rat endothelium-intact aorta assessed as reduction of acetylcholine-induced vasoconstriction at 100 uM in presence of L-Arg2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1629631Toxicity in mouse J744A.1 cells assessed as induction of apoptosis up to 1 mM after 2.5 hrs by Hoechst 33342/DAPI/GFP staining based fluorescence microscopic analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.
AID756825Induction of NOx production in Wistar rat liver homogenates at 100 uM after 1 hr by Griess test in presence of L-NAME2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID326380Inhibition of bovine liver arginase2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
N(delta)-Methylated L-arginine derivatives and their effects on the nitric oxide generating system.
AID756824Induction of NOx production in Wistar rat renal cortex homogenates at 100 uM after 1 hr by Griess test in presence of L-NAME2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID415946Binding affinity to iNOS with heme domain construct assessed as spectral binding constant by spectral assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
4,4-Difluorinated analogues of l-arginine and N(G)-hydroxy-l-arginine as mechanistic probes for nitric oxide synthase.
AID756829Induction of NOx production in Wistar rat liver homogenates at 100 uM after 1 hr by Griess test2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1629634Substrate activity at iNOS in LPS-stimulated mouse J744A.1 cells assessed as increase in NO release at 1 mM incubated for 2.5 hrs by Hoechst 33342/DAF-FM-DA staining based fluorescence microscopic analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.
AID756820Induction of NOx production in Wistar rat renal cortex homogenates at 100 uM after 1 hr by Griess test in presence of gamma-glutamyl transpeptidase2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID756811Vasodilatory activity in Wistar rat endothelium-intact aorta assessed as reduction of acetylcholine-induced vasoconstriction at 100 uM in presence of ODQ2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID756830Induction of xanthine/xanthine oxidase-mediated NOx production at 100 uM after 1 hr by Griess test2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1724057Inhibition of human Arg2 at pH 7.52020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Boronic acid-based arginase inhibitors in cancer immunotherapy.
AID756827Induction of NOx production in Wistar rat renal medullar homogenates at 100 uM after 1 hr by Griess test2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID415945Activity of iNOS assessed as oxidation of oxyhemoglobin to methemoglobin by indirect spectral assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
4,4-Difluorinated analogues of l-arginine and N(G)-hydroxy-l-arginine as mechanistic probes for nitric oxide synthase.
AID756823Induction of NOx production in Wistar rat renal medullar homogenates at 100 uM after 1 hr by Griess test in presence of L-NAME2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1724055Inhibition of rat Arg1 at pH 7.42020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Boronic acid-based arginase inhibitors in cancer immunotherapy.
AID1629629Toxicity in mouse J744A.1 cells assessed as appearance of cell blebbing up to 1 mM after 2.5 hrs by Hoechst 33342/DAPI/GFP staining based fluorescence microscopic analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.
AID756812Vasodilatory activity in Wistar rat endothelium-intact aorta assessed as reduction of acetylcholine-induced vasoconstriction at 100 uM in presence of hemoglobin2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1189987Displacement of imidazole from Bacillus subtilis NOS in presence of 50 uM H4B2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Structure-based design of bacterial nitric oxide synthase inhibitors.
AID756821Induction of NOx production in Wistar rat liver homogenates at 100 uM after 1 hr by Griess test in presence of gamma-glutamyl transpeptidase2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure.
AID1811Experimentally measured binding affinity data derived from PDB2001Biochemistry, Mar-06, Volume: 40, Issue:9
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Biochemistry, Mar-06, Volume: 40, Issue:9
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (135)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's49 (36.30)18.2507
2000's59 (43.70)29.6817
2010's24 (17.78)24.3611
2020's3 (2.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.40 (24.57)
Research Supply Index4.94 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.16%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other136 (97.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]